Helical CT of prostate cancer: Early clinical experience

American Journal of Roentgenology

Volumn 175, Issue 2, 2000, Pages 343-346

  Prando, Adilson ^a,b   Wallace, Sidney ^a  

^a Radiological Center of Campinas   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0033860017     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.175.2.1750343     Document Type: Article

References (16)

1. Brown G, Macvicar DA, Ayton V, Husband JE. The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radial 1995;50:601-606
2. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997;203:645-652
3. Rifkin MD. Staging of prostate cancer: clinical and imaging considerations. In: Rifkin MD, ed. Ultrasound of the prostate. Philadelphia: Lippincott-Raven, 1997:263-290
4. Arcangeli CG, Omstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997;24:299-306
5. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997;158:2162-2I67
6. Letran JL, Blase AB, Loberiza FR, Meyer GE, Ransom SD, Brawer MK. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specimen antigen ratio in predicting prostatic carcinoma. J Urol 1998;160:426-429
7. Kelly IM, Lees WR, Rickards D. Prostate cancer and the role of color Doppler US. Radiology 1993;189:153-156
8. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and potential applica-lions of color Doppler US scanning. Radiology 1993; 186:509-513
9. BroeRL. The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997;49:31-34
10. Lavoipierre AM, Snow RM, Frydenberg M, et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR 1998:171:205-210
11. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-1574
12. Stroumbakis N, Cookson MS, Reuter VE, FairWR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997;49:113-118
13. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159:1247-1250
14. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997;158:505-509
15. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RV. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 1998:51:186-195
16. Price JM, Davidson AJ. Computed tomography in the evaluation of the suspected carcinomatous prostate. Urol Radial 1979; 1:39-42